Advisors Preferred’s Regeneron Pharmaceuticals REGN Stock Holding History

Advisors Preferred’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-807	Closed	-$593K	–	218
2022 Q3	$593K	Sell	807 -286	-26%	-$180K	0.3%	24
2022 Q2	$646K	Sell	1,093 -6,749	-86%	-$4.39M	0.17%	75
2022 Q1	$5.45M	Buy	7,842 +2,450	+45%	+$1.55M	0.44%	27
2021 Q4	$3.38M	Buy	5,392 +3,269	+154%	+$2.01M	0.33%	49
2021 Q3	$1.21M	Buy	+2,123	New	+$1.32M	0.17%	52
2021 Q2	–	Sell	-3,785	Closed	-$1.8M	–	216
2021 Q1	$1.8M	Buy	+3,785	New	+$1.84M	0.26%	34
2020 Q4	–	Sell	-2,121	Closed	-$1.19M	–	197
2020 Q3	$1.19M	Buy	2,121 +542	+34%	+$329K	0.24%	29
2020 Q2	$962K	Buy	+1,579	New	+$896K	0.27%	30
2020 Q1	–	Sell	-1,547	Closed	-$581K	–	232
2019 Q4	$581K	Buy	+1,547	New	+$520K	0.16%	51

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Advisors Preferred's REGN Position: Q4 2022 in Review

Advisors Preferred sold out of Regeneron Pharmaceuticals (REGN) in Q4 2022, closing a stake of 807 shares — an estimated $593K sold.

Advisors Preferred first reported a position in REGN in Q4 2019 and held it in 9 quarters. The position peaked at $5.45M in Q1 2022. 1,158 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

Advisors Preferred reported no remaining Regeneron Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Advisors Preferred sold 807 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $593K.
Advisors Preferred first reported a position in Regeneron Pharmaceuticals in Q4 2019 and held it in 9 quarters.
Advisors Preferred's Regeneron Pharmaceuticals position peaked at $5.45M in Q1 2022.
1,158 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Advisors Preferred's 13F filing for Q4 2022, filed 9 Feb 2023.